Found: 104
Select item for more details and to access through your institution.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. E63, doi. 10.1002/ajh.27180
- By:
- Publication type:
- Article
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. 193, doi. 10.1002/ajh.27138
- By:
- Publication type:
- Article
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. 21, doi. 10.1002/ajh.27113
- By:
- Publication type:
- Article
Mast cell cytomorphology and treatment outcome in mast cell leukemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. E5, doi. 10.1002/ajh.27105
- By:
- Publication type:
- Article
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. E1, doi. 10.1002/ajh.27089
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 7, p. E165, doi. 10.1002/ajh.26933
- By:
- Publication type:
- Article
Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 6, p. E148, doi. 10.1002/ajh.26902
- By:
- Publication type:
- Article
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative cases.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. E76, doi. 10.1002/ajh.26845
- By:
- Publication type:
- Article
A phase II study of combination d aunorubicin, cytarabine (A ra‐c), and nilotinib (TA signa) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 472, doi. 10.1002/ajh.26831
- By:
- Publication type:
- Article
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. 282, doi. 10.1002/ajh.26778
- By:
- Publication type:
- Article
Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. E474, doi. 10.1002/ajh.26749
- By:
- Publication type:
- Article
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. E433, doi. 10.1002/ajh.26714
- By:
- Publication type:
- Article
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real‐world setting.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 10, p. E377, doi. 10.1002/ajh.26672
- By:
- Publication type:
- Article
A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1127, doi. 10.1002/ajh.26630
- By:
- Publication type:
- Article
Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1013, doi. 10.1002/ajh.26589
- By:
- Publication type:
- Article
Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E214, doi. 10.1002/ajh.26539
- By:
- Publication type:
- Article
Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E210, doi. 10.1002/ajh.26533
- By:
- Publication type:
- Article
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. 630, doi. 10.1002/ajh.26498
- By:
- Publication type:
- Article
Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS‐RS) but not in MDS/MPN‐RS‐T.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E109, doi. 10.1002/ajh.26448
- By:
- Publication type:
- Article
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. 322, doi. 10.1002/ajh.26447
- By:
- Publication type:
- Article
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 2, p. E62, doi. 10.1002/ajh.26417
- By:
- Publication type:
- Article
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. E433, doi. 10.1002/ajh.26334
- By:
- Publication type:
- Article
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. 1450, doi. 10.1002/ajh.26321
- By:
- Publication type:
- Article
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. 781, doi. 10.1002/ajh.26186
- By:
- Publication type:
- Article
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. E108, doi. 10.1002/ajh.26112
- By:
- Publication type:
- Article
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 12, p. 1511, doi. 10.1002/ajh.25978
- By:
- Publication type:
- Article
A population‐based study of chronic eosinophilic leukemia‐not otherwise specified in the United States.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. E257, doi. 10.1002/ajh.25906
- By:
- Publication type:
- Article
Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS‐CoV‐2 pandemic.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 8, p. E203, doi. 10.1002/ajh.25853
- By:
- Publication type:
- Article
Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like (Philadelphia chromosome like) B‐acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 3, p. E68, doi. 10.1002/ajh.25729
- By:
- Publication type:
- Article
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 7, p. 767, doi. 10.1002/ajh.25488
- By:
- Publication type:
- Article
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3‐ITD mutational status.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 12, p. E401, doi. 10.1002/ajh.25290
- By:
- Publication type:
- Article
Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 12, p. E398, doi. 10.1002/ajh.25287
- By:
- Publication type:
- Article
The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. E355, doi. 10.1002/ajh.25239
- By:
- Publication type:
- Article
Pre‐anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 6, p. E144, doi. 10.1002/ajh.25083
- By:
- Publication type:
- Article
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 65, doi. 10.1002/ajh.24939
- By:
- Publication type:
- Article
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. E626, doi. 10.1002/ajh.24866
- By:
- Publication type:
- Article
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 9, p. 866, doi. 10.1002/ajh.24780
- By:
- Publication type:
- Article
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 5, p. 365, doi. 10.1002/ajh.23410
- By:
- Publication type:
- Article
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
- Published in:
- Systematic Reviews, 2018, v. 7, n. 1, p. N.PAG, doi. 10.1186/s13643-018-0805-7
- By:
- Publication type:
- Article
First-Cycle CSF Use in Breast Cancer and NHL: Guidelines and Recommendations.
- Published in:
- Oncology (08909091), 2006, v. 20, p. 7
- By:
- Publication type:
- Article
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
- Published in:
- Transplant Infectious Disease, 2016, v. 18, n. 6, p. 913, doi. 10.1111/tid.12612
- By:
- Publication type:
- Article
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).
- Published in:
- Journal of Blood Medicine, 2010, v. 1, p. 115
- By:
- Publication type:
- Article
Nelarabine in Adult Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma(T-ALL/T-LBL): The Mayo Clinic Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S253, doi. 10.1016/j.clml.2017.07.015
- By:
- Publication type:
- Article
ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Leukemic Polyradiculopathy Due to Blastic Plasmacytoid Dendritic Cell Neoplasm.
- Published in:
- JAMA Dermatology, 2015, v. 151, n. 8, p. 938, doi. 10.1001/jamaneurol.2015.0830
- By:
- Publication type:
- Article
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01028-4
- By:
- Publication type:
- Article
One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00972-x
- By:
- Publication type:
- Article
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00922-7
- By:
- Publication type:
- Article
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00891-x
- By:
- Publication type:
- Article
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00821-x
- By:
- Publication type:
- Article